The FDA said 'additional review' and court cases led it to roll back the ban.
The Food and Drug Administration announced Thursday it had formally withdrawn marketing denial orders it had issued to Juul Labs in 2022, making it possible for the once-dominant e-cigarette manufacturer to pursue authorization for its sales.The marketing denial orders were effectively paused by the agency not long after they were issued, leaving the product in limbo for years amid court litigation and 'additional review' the FDA said it was conducting of Juul's applications.
'In parallel, in the time since the MDOs were administratively stayed in 2022, the FDA has gained more experience with various scientific issues regarding e-cigarette products, and there have been new litigation outcomes in cases about MDOs for e-cigarette products from other manufacturers,' the FDA said in a statement.The agency said that rescinding the marketing denial orders was not the same as a new decision on whether to formally authorize sales of the e-cigarettes.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA reverses marketing ban on Juul e-cigarettesRob Wile is a breaking business news reporter for NBC News Digital.
Read more »
Colorado to use $20 million from Juul vaping settlement to fund youth mental health servicesThe Colorado Department of Law will use settlement money from a nationwide lawsuit against e-cigarette maker Juul Labs to provide up to $20 million in grants to community groups working to increase…
Read more »
Colorado to spend $20 million of Juul settlement on grant program to improve youth mental healthColorado will spend $20 million of a $31.7 million lawsuit settlement with e-cigarette manufacturer Juul Labs Inc. on a grant program aimed at improving youth mental health.
Read more »
FDA objects to ecstasy for treating PTSD patientsA nonbinding Food and Drug Administration panel rejected a proposal to use MDMA, or ecstasy, to treat post-traumatic stress disorder.
Read more »
Psychedelic Stocks Tank After FDA Advisors Shoot Down MDMA Therapy For PTSDRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
FDA panel rejects the use of psychedelic drug MDMA to treat patients with PTSDRooted in fact-based, transparent reporting, Newsy is an award-winning opinion-free network owned by the E.W. Scripps Company that is relentlessly focused on “the why” of every story and seeks to enable a more intimate and immersive understanding of the issues that matter.
Read more »